1|Page
NR 565 ADVANCED
PHARMACOLOGY MIDTERM EXAM
REVIEW QUESTIONS WITH
ACCURATE ANSWERS | MULTIPLE
CHOICES A+ GRADED
Abrupt stopping of Beta Blockers
..... ANSWER ...... Can increase the incidence and intensity of
angina attacks and may precipitate MI.
Diuretics and Sulfa Allergy
..... ANSWER ...... Considerations include patients with severe renal
impairment, cardiovascular issues, history of gout, diabetes, and
hyperlipidemia.
Monitoring parameters for Diuretics
..... ANSWER ...... Weight, vitals, blood glucose, BUN &
creatinine/kidney function, electrolytes - sodium, potassium, calcium,
magnesium.
Heart failure treatment
..... ANSWER ...... Includes diuretics, RAAS inhibitors, beta blockers,
and digoxin.
ACE-I
,2|Page
..... ANSWER ...... Prescribed in response to fibrotic changes as it
inhibits cardiac remodeling.
Entresol
..... ANSWER ...... Sacubitril/valsartan, an angiotensin receptor
neprilysin inhibitor (ANRI).
ASCVD risk score
..... ANSWER ...... Determines the patient's absolute risk of
developing clinical coronary disease over the next 10 years; defines
high risk as 7.5% or greater.
Screening for ASCVD in children
..... ANSWER ...... Should be done between ages 9 and 11 and again
at ages 19 and 21.
Screening for ASCVD in adults
..... ANSWER ...... Every 5 years after the age of 20.
Hyperlipidemia
..... ANSWER ...... Excessive amounts of lipids in the blood.
Statin drugs
..... ANSWER ...... Avoid use in children under the age of 10.
,3|Page
Ezetimibe usage
..... ANSWER ...... Can be used in monotherapy or as adjunct
therapy with a statin or a fibrate.
Ezetimibe
..... ANSWER ...... Can be used to manage cholesterol if statins are
causing side effects.
Bile acid sequestrants
..... ANSWER ...... Can be used to manage cholesterol if statins are
causing side effects.
Fibrates
..... ANSWER ...... Can be used to manage cholesterol if statins are
causing side effects.
Non-statin cholesterol-lowering therapy
..... ANSWER ...... Liver issues, gallbladder issues and constipation
should be looked at prior to starting.
Organic nitrates
..... ANSWER ...... Have a direct relaxant effect on vascular smooth
muscles, improving oxygen supply to the myocardium.
Therapeutic action of organic nitrates
, 4|Page
..... ANSWER ...... Dilation of coronary vessels improves oxygen
supply to the myocardium.
Most appropriate treatment for osteoarthritis
..... ANSWER ...... Non-opioid medications - NSAIDs, cox-2
inhibitors; nonpharmacologic treatments - heat/cold, yoga, physical
therapy, exercise, healthy weight.
Complications of untreated gout
..... ANSWER ...... Erosion and irreversible joint damage, renal
damage, tophi (stone deposits in joints and tissues).
Colchicine patient education
..... ANSWER ...... Start taking this medicine at the first sign of the
attack for best results.
Colchicine prophylaxis dosage
..... ANSWER ...... 0.6 mg once or twice daily (maximum, 1.2 mg/24
h).
Long term use of allopurinol
..... ANSWER ...... Can cause severe cutaneous adverse reaction
(SCAR), rash, fever, eosinophilia, liver and kidney dysfunction.
NR 565 ADVANCED
PHARMACOLOGY MIDTERM EXAM
REVIEW QUESTIONS WITH
ACCURATE ANSWERS | MULTIPLE
CHOICES A+ GRADED
Abrupt stopping of Beta Blockers
..... ANSWER ...... Can increase the incidence and intensity of
angina attacks and may precipitate MI.
Diuretics and Sulfa Allergy
..... ANSWER ...... Considerations include patients with severe renal
impairment, cardiovascular issues, history of gout, diabetes, and
hyperlipidemia.
Monitoring parameters for Diuretics
..... ANSWER ...... Weight, vitals, blood glucose, BUN &
creatinine/kidney function, electrolytes - sodium, potassium, calcium,
magnesium.
Heart failure treatment
..... ANSWER ...... Includes diuretics, RAAS inhibitors, beta blockers,
and digoxin.
ACE-I
,2|Page
..... ANSWER ...... Prescribed in response to fibrotic changes as it
inhibits cardiac remodeling.
Entresol
..... ANSWER ...... Sacubitril/valsartan, an angiotensin receptor
neprilysin inhibitor (ANRI).
ASCVD risk score
..... ANSWER ...... Determines the patient's absolute risk of
developing clinical coronary disease over the next 10 years; defines
high risk as 7.5% or greater.
Screening for ASCVD in children
..... ANSWER ...... Should be done between ages 9 and 11 and again
at ages 19 and 21.
Screening for ASCVD in adults
..... ANSWER ...... Every 5 years after the age of 20.
Hyperlipidemia
..... ANSWER ...... Excessive amounts of lipids in the blood.
Statin drugs
..... ANSWER ...... Avoid use in children under the age of 10.
,3|Page
Ezetimibe usage
..... ANSWER ...... Can be used in monotherapy or as adjunct
therapy with a statin or a fibrate.
Ezetimibe
..... ANSWER ...... Can be used to manage cholesterol if statins are
causing side effects.
Bile acid sequestrants
..... ANSWER ...... Can be used to manage cholesterol if statins are
causing side effects.
Fibrates
..... ANSWER ...... Can be used to manage cholesterol if statins are
causing side effects.
Non-statin cholesterol-lowering therapy
..... ANSWER ...... Liver issues, gallbladder issues and constipation
should be looked at prior to starting.
Organic nitrates
..... ANSWER ...... Have a direct relaxant effect on vascular smooth
muscles, improving oxygen supply to the myocardium.
Therapeutic action of organic nitrates
, 4|Page
..... ANSWER ...... Dilation of coronary vessels improves oxygen
supply to the myocardium.
Most appropriate treatment for osteoarthritis
..... ANSWER ...... Non-opioid medications - NSAIDs, cox-2
inhibitors; nonpharmacologic treatments - heat/cold, yoga, physical
therapy, exercise, healthy weight.
Complications of untreated gout
..... ANSWER ...... Erosion and irreversible joint damage, renal
damage, tophi (stone deposits in joints and tissues).
Colchicine patient education
..... ANSWER ...... Start taking this medicine at the first sign of the
attack for best results.
Colchicine prophylaxis dosage
..... ANSWER ...... 0.6 mg once or twice daily (maximum, 1.2 mg/24
h).
Long term use of allopurinol
..... ANSWER ...... Can cause severe cutaneous adverse reaction
(SCAR), rash, fever, eosinophilia, liver and kidney dysfunction.
